Alcami to manufacture PharmaTher’s proprietary ketamine products
The CDMO will supply expertise in GMP sterile fill-finish manufacturing and controlled-substances
Three weeks after Alcami announced it was investing an additional $31 million to expand its sterile CDMO operation in Charleston, SC to increase its fill-finish and lyophilisation capacity, the company has agreed to manufacture PharmaTher's proprietary ketamine products.
PharmaTher, a clinical-stage psychedelics biotech company, is building a specialty ketamine-based product pipeline to support its internal product pipeline.
Alcami will support PharmaTher’s global ketamine product development and commercialisation plans by supplying expertise in GMP sterile fill-finish manufacturing and controlled substances.
The ability to manufacture and supply ketamine products in different dosage forms enables PharmaTher to guarantee delivery on its product pipeline as well as form partnerships with research labs, ketamine clinics and pharmaceutical companies that are seeking a secure supply of cGMP ketamine and ketamine products for current portfolios; exploring alternative dose forms for multiple existing indications; and requiring support to develop and commercialise specific ketamine products for new indications.
PharmaTher’s proprietary ketamine drug products are expected to be available for FDA Phase III clinical studies and commercial use during the latter half of 2022.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance